×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Leukemia
Beth Fand Incollingo
Chronic lymphocytic leukemia can now be managed as a long-term condition, and there are new ways loved ones can help.
Jason M. Broderick
The FDA has granted a priority designation to a supplemental new drug application (sNDA) for Imbruvica (ibrutinib) for use in combination with Gazyva (obinutuzumab) for the frontline treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Kim Johnson
I shared some advice with another soon-to-be caregiver.
Brielle Urciuoli
The drug was approved for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma. And was granted an accelerated approval for follicular lymphoma.
Brielle Urciuoli
While a pediatric cancer diagnosis can obviously impact the child experiencing the disease, psychosocial effects can differentiate how each parent is affected, too.
Chuck Green
Techniques open a field of opportunity for stem cell transplant recipients.
Brielle Urciuoli
The Food and Drug Administration (FDA) approved the use of Lumoxiti (moxetumomab pasudotox-tdfk) for patients with relapsed or refractory hairy cell leukemia (HCL) who previously had at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Equipping with knowledge to improve patient-physician communication and understanding the disease.
Katie Kosko
An expert provides tips for maximizing time with your oncologist and adhering to oral medication.